Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Collaborator: National Natural Science Foundation of China
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Adult chronic ITP, age 18 to 60

Exclusion Criteria:

• pregnant woman with ITP; liver disease and kidney disease; allergy to rituximab